This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 1 of 2 for:    Phase 1/2 GBT440-001
Previous Study | Return to List | Next Study

An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Global Blood Therapeutics Identifier:
First received: January 19, 2017
Last updated: February 3, 2017
Last verified: January 2017

This is an open label, single arm study which will enroll up to 16 subjects with SCD who previously participated in the GBT440-001 study.

Dosing of study drug will be for 2 to 6 months, depending on subject's dose assignment in the last administration of study drug in GBT440-001.

The primary objective of the study is to evaluate the safety and tolerability of up to a total of 6 months dosing of subjects with SCD who participated in the GBT440-001 study.

Condition Intervention Phase
Sickle Cell Disease Drug: GBT440 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: An Open Label Single Arm Extension Study to Further Evaluate the Safety, Tolerability and Treatment Response of GBT440 in Patients With Sickle Cell Disease Who Participated in the Phase 1 Study GBT440-001

Resource links provided by NLM:

Further study details as provided by Global Blood Therapeutics:

Primary Outcome Measures:
  • The Incidence of Treatment-Emergent Adverse Events during dosing of GBT440 for up to 6 months. [ Time Frame: 2 - 6 months ]
    The safety evaluation will include physical examinations, blood pressure, clinical laboratory tests (hematology, serum biochemistry) and adverse events.

Secondary Outcome Measures:
  • To assess the efficacy of GBT440 as measured by improvements in anemia [ Time Frame: 2 - 6 months ]
    Measurement of haemoglobin

  • To observed pharmacokinetics in plasma and whole blood. [ Time Frame: 2 - 6 months ]
    Measure maximum plasma concentration (Cmax)

  • To characterize the effect of GBT440 on hemolysis. [ Time Frame: 2 - 6 months ]
    Measurement of hemolysis include unconjugated bilirubin.

Estimated Enrollment: 16
Study Start Date: August 2016
Estimated Study Completion Date: August 2017
Estimated Primary Completion Date: May 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Single Arm
Single Arm / open label
Drug: GBT440
Oral drug


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female subjects with SCD aged 18 to 60 years inclusive and >50 kg who have participated in the GBT440-001 study.
  2. Subjects, who if female and of child bearing potential, agree to continue to use highly effective methods of contraception prior to enrollment in this study and for 3 months after the last dose of study drug.
  3. Subjects, who if male are willing to continue to use barrier methods of contraception, prior to enrollment in this study to 3 months after the last dose of study drug.

Exclusion Criteria:

  1. Subjects requiring chronic transfusion therapy.
  2. Subjects receiving a blood transfusion within 30 days of enrollment in this study.
  3. Female subjects who are pregnant, trying to become pregnant or lactating.
  4. Subjects who have a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders, or additional risk factors for torsades de pointe (e.g., heart failure, hypokalemia, personal or family history of long QTc interval).
  5. Subjects who have a significant infection or known inflammatory process on admission to this study.
  6. Subjects who have acute gastrointestinal symptoms at the time of admission (e.g. nausea, vomiting, diarrhoea, heartburn).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT03041909

United Kingdom
The BRC Research Facility, Floor 15 The Tower Wing
London, United Kingdom, SE1 9RT
Sponsors and Collaborators
Global Blood Therapeutics
Study Director: Josh Lehrer-Graiwer, MD Global Blood Therapeutics, Inc.
Principal Investigator: Timothy Mant, FRCP, FFPM Quintiles, Inc.
  More Information

Responsible Party: Global Blood Therapeutics Identifier: NCT03041909     History of Changes
Other Study ID Numbers: GBT440-024
Study First Received: January 19, 2017
Last Updated: February 3, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn processed this record on September 25, 2017